| Ticker: ATCI | 520 North Semoran Boulevard, Suite 180 | |
| Exchange: NASDAQ-National Market | Orlando, Florida 32807 | |
| Industry: Manufacturing | (407) 282-1262 |
| Type of Shares: | Common Shares | Filing Date: | 3/8/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 5/1/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $9.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $20,000,000 | Selling: | $0.32 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,749,950 |
| Manager | Tier | Phone |
| Hanifen, Imhoff Inc. | Lead Manager | (303) 296-2300 |
| Cruttenden Roth Incorporated | Co-manager | (800) 678-9147 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/95 | 12/31/95 | 12/31/95 | |||
| Revenue: | $0.00 | $0.00 | Assets: | $0.80 | |
| Net Income: | -$2.70 | -$4.10 | Liabilities: | $4.36 | |
| EPS: | -$0.72 | Equity: | -$3.56 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs and develops laser vision correction devices. The Company's technology combines eye tracking with a narrow beam excimer laser to treat common refractive vision disorders such as myopia, hyperopia and astigmatism. The Company's objective is to improve refractive surgical outcomes for these conditions over those achieved by earlier laser vision correction systems. Vision correction is one of the largest medical markets, with over 110 million people in the United States using eyeglasses or contact lenses. Within this group, approximately 60-70 million people are myopic. Industry sources estimate that Americans spent approximately $13 billion on eyeglasses, contact lenses and other vision correction products and services in 1994. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to continue clinical trials and product development of the T-PRK System for myopia and other refractive disorders; to establish and launch sales and service outside the U.S.; to establish in-house manufacturing and assembly capabilities; and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.